Wildland Firefighters Congressional Gold Medal Act

Senate Bill

S. 142

119th Congress

Wildland Firefighters Congressional Gold Medal Act

In Committee

Introduced:Sep 16, 2025

Primary Sponsor

Amy Klobuchar

D - MN

Cosponsors

10

Quick Stats

Policy Area

Health

Summary

This bill aims to prevent drug companies from making deals that delay the release of cheaper generic and biosimilar drugs. It gives the Federal Trade Commission the power to go after any agreements where a brand-name drug maker pays a generic or biosimilar maker to hold off on releasing their product.

Latest Action

Placed on Senate Legislative Calendar under General Orders. Calendar No. 20.

Introduced9/16/2025

StatusRead twice and referred to the Committee on Banking, Housing, and Urban Affairs. (text: CR S231-232)

ChamberSenate

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

Wildland Firefighters Congressional Gold Medal Act

This bill aims to prevent drug companies from making deals that delay the release of cheaper generic and biosimilar drugs. It gives the Federal Trade Commission the power to go after any agreements where a brand-name drug maker pays a generic or biosimilar mak

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill aims to prevent drug companies from making deals that delay the release of cheaper generic and biosimilar drugs. It gives the Federal Trade Commission the power to go after any agreements where a brand-name drug maker pays a generic or biosimilar maker to hold off on releasing their product.

Bill Number: 142
Introduced: 9/16/2025
Status: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs. (text: CR S231-232)
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: Wildland Firefighters Congressional Gold Medal Act
Bill Number: 142
Sponsor: No sponsor
Status: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs. (text: CR S231-232)
Introduced: 9/16/2025
Summary: This bill aims to prevent drug companies from making deals that delay the release of cheaper generic and biosimilar drugs. It gives the Federal Trade Commission the power to go after any agreements where a brand-name drug maker pays a generic or biosimilar maker to hold off on releasing their produc

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill aims to prevent drug companies from making deals that delay the release of cheaper generic and biosimilar drugs. It gives the Federal Trade Commission the power to go after any agreements where a brand-name drug maker pays a generic or biosimilar maker to hold off on releasing their product.

Last updated: 12/29/2025

Official Summary

Congressional Research Service summary

Preserve Access to Affordable Generics and Biosimilars Act This bill authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar. An agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects. When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains the complete agreement and any agreements related to that main agreement, including descriptions of any oral agreements or representations. The bill imposes penalties for violations of this bill, including the forfeiture of the 180-day marketing exclusivity period for a generic drug.

Key Points

Main provisions of the bill

Authorizes the FTC to take action against drug company agreements that delay cheaper generic and biosimilar drug releases
Presumes that any agreement where a generic/biosimilar maker receives payment to limit their product is anticompetitive and illegal
Allows some exceptions, like allowing the generic/biosimilar to launch early or covering litigation costs

How This Impacts Americans

Potential effects on citizens and communities

This bill would impact consumers by potentially speeding up the availability of less expensive generic and biosimilar drugs, saving people money on their medications. It would also affect brand-name and generic/biosimilar drug companies, limiting their ability to make deals that delay competition.

Policy Areas

Primary Policy Area

Health

Related Subjects

Administrative law and regulatory procedures

Civil actions and liability

Competition and antitrust

Contracts and agency

Federal Trade Commission (FTC)

Intellectual property

Judicial review and appeals

Licensing and registrations

Manufacturing

Marketing and advertising

+1 more

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

142, 119th Congress (2025). "Wildland Firefighters Congressional Gold Medal Act". Source: Voter's Right Platform. https://votersright.org/bills/118-s-142